Mayo Clinic in Florida

Running trials

• Not yet recruiting

  Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida

  NCT06607874· Source

• Not yet recruiting

  Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

  NCT07281547· Phase 4· Source

• Recruiting

  Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

  NCT06770023· Phase 1· Source

• Not yet recruiting

  Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

  NCT07769047· Phase 4· Source

• Recruiting

  Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

  NCT07708961· Phase 2· Source

• Recruiting

  Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors

  NCT07545837· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Source

• Recruiting

  A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men

  NCT07126548· Source

• Recruiting

  Smart Symptom Tracking ALEX Application for Tracking and Monitoring Gastrointestinal Health, Smart Horizons Pilot Trial

  NCT07618273· Source

• Recruiting

  The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

  NCT07218445· Phase 4· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· Phase 2· Source

• Recruiting

  Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

  NCT06997094· Phase 1· Source

• Recruiting

  Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

  NCT07073794· Phase 2· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

  NCT07287397· Phase 1/2· Source

• Recruiting

  The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

  NCT07285044· Phase 2· Source

• Recruiting

  BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

  NCT07226856· Phase 2· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Source

• Recruiting

  A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

  NCT07227532· Source

• Recruiting

  A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

  NCT07074756· Source

• Recruiting

  Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy

  NCT06940271· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Source

• Recruiting

  Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

  NCT07091864· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  NCT07000084· Phase 3· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Source

• Recruiting

  Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  NCT06724237· Phase 3· Source

• Recruiting

  Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

  NCT06676579· Phase 2· Source

• Recruiting

  A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials

  NCT05655494· Source

• Recruiting

  Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

  NCT06918132· Phase 2· Source

• Recruiting

  A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  NCT06892548· Phase 1/2· Source

• Enrolling by invitation

  Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

  NCT07057310· Phase 4· Source

• Recruiting

  In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

  NCT06704191· Phase 1/2· Source

• Recruiting

  AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

  NCT06665165· Phase 1· Source

• Recruiting

  Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  NCT06834373· Phase 2· Source

• Recruiting

  Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

  NCT06797193· Source

• Active, not recruiting

  A Study of a Novel Precision Medicine Approach For Obesity

  NCT06814938· Phase 4· Source

• Enrolling by invitation

  Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

  NCT06744595· Source

• Recruiting

  Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

  NCT06625034· Phase 3· Source

• Recruiting

  Knee Injections for Obese Patients With Knee Arthritis

  NCT06782529· Phase 4· Source

• Recruiting

  Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

  NCT06475989· Phase 3· Source

• Recruiting

  Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

  NCT06465316· Phase 1· Source

• Recruiting

  Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning

  NCT06200116· Source

• Recruiting

  Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

  NCT05647265· Phase 2· Source

• Recruiting

  Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

  NCT06630104· Source

• Recruiting

  Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  NCT06116682· Phase 2· Source

• Recruiting

  Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

  NCT06639074· Phase 2· Source

• Recruiting

  Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

  NCT06337318· Phase 3· Source

Showing 50 of 199.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer14 recruiting
• Childhood cancers13 recruiting
• Prostate cancer12 recruiting
• Bladder cancer9 recruiting
• Colorectal cancer8 recruiting
• Multiple myeloma8 recruiting
• Endometrial cancer7 recruiting
• Glioblastoma7 recruiting
• Kidney cancer7 recruiting
• Liver and biliary tract cancer7 recruiting
• Melanoma7 recruiting
• Ovarian cancer7 recruiting
• Sarcoma7 recruiting
• Pancreatic cancer6 recruiting
• Cervical cancer5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Head and neck cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Neuroendocrine tumours4 recruiting
• Obesity4 recruiting
• Acute myeloid leukaemia3 recruiting
• ALS (motor neurone disease)3 recruiting
• Follicular lymphoma3 recruiting
• Triple-negative breast cancer3 recruiting
• Alzheimer disease2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Mantle cell lymphoma2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Thyroid cancer2 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Hodgkin lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Lewy body dementia1 recruiting
• Mesothelioma1 recruiting
• Parkinson disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

  NCT06703996· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· Source

• Completed

  Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

  NCT06470750· Source

• Completed

  Extracellular Vesicle Cargo in Obesity and Type 2 Diabetes

  NCT06401876· Source

• Completed

  Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT05730712· Phase 2· Source

• Terminated

  CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

  NCT05689021· Phase 2· Source

• Completed

  iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

  NCT06535802· Source

• Completed

  A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

  NCT06151717· Source

• Completed

  Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

  NCT06037863· Source

• Completed

  Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

  NCT05979883· Source

• Terminated

  Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

  NCT04975516· Phase 2· Source

• Completed

  Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

  NCT05557162· Source

• Terminated

  Needle-Based Confocal Laser Endomicroscopy for Diagnosis of Lung Cancer in Patients With Peripheral Pulmonary Nodules

  NCT05556525· Source

• Completed

  An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

  NCT05560009· Source

• Terminated

  E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

  NCT05388877· Phase 1· Source

• Terminated

  Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

  NCT05393713· Phase 1· Source

• Terminated

  Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

  NCT05288062· Phase 2· Source

• Recruiting

  Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

  NCT05168163· Phase 2· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Source

• Completed

  Improving Wellbeing in Ischemic Heart Disease

  NCT04974541· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· Source

• Completed

  Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

  NCT04493060· Phase 2· Source

• Terminated

  Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

  NCT04230304· Phase 2· Source

• Terminated

  Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

  NCT04396535· Phase 2· Source

• Completed

  Molecular Mechanisms of Exercise Benefits to Insulin Resistant People

  NCT04158375· Source

• Terminated

  Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

  NCT04517838· Source

• Terminated

  Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

  NCT03765736· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Terminated

  Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

  NCT03979508· Phase 2· Source

• Completed

  Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)

  NCT04047810· Phase 1· Source

• Terminated

  Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

  NCT03879629· Phase 2· Source

• Terminated

  Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

  NCT03737994· Phase 2· Source

• Terminated

  Rifaximin in Patients With Diabetic Gastroparesis

  NCT04254549· Phase 2· Source

• Terminated

  Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

  NCT03865212· Phase 1· Source

• Completed

  Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

  NCT03960177· Early phase 1· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· Source

• Completed

  Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

  NCT03713294· Phase 2· Source

• Completed

  Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

  NCT03554083· Phase 2· Source

• Completed

  A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565· Phase 2· Source

• Terminated

  Preventing Lymphedema in Axillary Lymph Node Dissection

  NCT03428581· Source

• Completed

  Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

  NCT03477539· Phase 2· Source

• Completed

  Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674· Phase 2/3· Source

• Completed

  TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

  NCT03179904· Phase 2· Source

• Completed

  Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687· Phase 3· Source

• Completed

  Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

  NCT03080883· Phase 3· Source

• Completed

  Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

  NCT02484430· Phase 2· Source

• Completed

  The National Myelodysplastic Syndromes (MDS) Study

  NCT02775383· Source

• Completed

  Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

  NCT02697344· Phase 1· Source

• Completed

  Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

  NCT02649387· Phase 2· Source

Showing 50 of 66.